Mochi Health Review (2026): Is It Legit? Pricing, GLP-1 Options, Pros and Cons

Key takeaways

• Mochi Health (Mochi Health Corp., San Francisco) is a membership telehealth platform built around GLP-1 weight care, with clinicians from affiliated medical practices. On October 10, 2026 it listed compounded semaglutide (injection and a once-weekly pill), compounded tirzepatide and orforglipron, the brand GLP-1 drugs, sermorelin and NAD+, alongside hair, skin, mental-health and menopause care.
• Pricing has two parts: a membership ($79 month to month, $49 a month on a 12-month prepayment, or $119 for six months and $199 for twelve on the insured plan) and medication priced by dose. Compounded semaglutide cost $60 to $99 a month and compounded tirzepatide $90 to $199, shipping included.
• Care starts with a live 30-minute video visit with a provider you choose. Mochi does not name its pharmacies: you compare them in its marketplace, prices vary by pharmacy, and prescriptions may be moved between them.
• FDA's warning-letter database returned no letter addressed to Mochi on October 10, 2026. Its compounded GLP-1s sit in the narrow legal lane that has applied since the shortages ended, and its own blog says the formulations often include additives such as B12 or L-carnitine, which do not by themselves create that lane.
• Partly used periods are not refunded, medication is final once sent to a pharmacy, and disputes go to arbitration unless you opt out within 30 days. Trustpilot showed 4.5 of 5 from 19,304 reviews.

Disclosure. The Peptide Doctrine is an independent editorial project. It currently has no sponsor and runs no advertising: we accept no payment for reviews, rankings or placements, we run no affiliate links, and we do not sell or link to "research-use" peptide vendors. Content is educational and is not medical advice.

Mochi Health at a glance

Facts as published on Mochi's own pages and read on October 10, 2026, unless another source is named. The price arithmetic is in our Mochi Health cost breakdown.

How we reviewed Mochi Health

On October 10, 2026 we read Mochi's home, weight-loss, longevity and Medicare pages, its medication pages for each GLP-1 product, sermorelin and NAD+, its FAQ, refund and pharmacy-partner pages, its terms of use (updated September 22, 2026), and two posts on its blog: the per-dose pricing announcement and an explainer on GLP-1 additives. We searched FDA's warning-letter database for Mochi, its corporate name and its affiliated practices, read Trustpilot through a text-only reader (the Better Business Bureau's site returned no profile to us), and ran PubMed searches for the compounded products Mochi sells.

We did not sign up, pay or take a consultation, so nothing here describes a customer experience, and we quote no individual reviews. We did not contact Mochi before publication. No company paid for this page or saw it before publication. Every figure carries its date; corrections go to editors@peptidedoctrine.com.

What Mochi Health offers

Weight care is the core. The weight-loss menu lists compounded semaglutide as a weekly injection and as a once-weekly pill, compounded tirzepatide injections, compounded orforglipron as a daily tablet, metformin, and the brand drugs Zepbound, Mounjaro, Wegovy, the Wegovy pill, Ozempic and Foundayo. Mochi's product listings state that compounded medications are not approved or evaluated by FDA, and each medication page says the product requires the membership (Mochi medication pages). The FAQ adds other drugs its providers often prescribe, including liraglutide, topiramate, bupropion, naltrexone and orlistat, says eligibility follows clinical guidelines for obesity or overweight with a weight-related condition, and describes a pediatrics program for patients under 18 (Mochi FAQ).

Compounded doses come in Mochi's own steps. Tirzepatide is sold at weekly doses of 2.2, 4.4, 6.6, 8.8, 11.24, 13.2 and 16.6 mg, and injectable semaglutide from 0.22 to 6.48 mg (Mochi medication pages). Those steps do not match the brands: Zepbound rises in 2.5 mg steps to a 15 mg maximum, as our tirzepatide dosage chart shows, so Mochi's top tirzepatide step is above the label maximum. Our microdosing explainer covers what is known about the lower end.

Additives are part of the formula. A Mochi blog post updated September 18, 2026 says compounded GLP-1 formulations often include methylcobalamin or cyanocobalamin (B12), L-carnitine, glycine, niacinamide, pyridoxine or NAD+, chosen by the provider for each patient (Mochi additives post). A survey of compounding websites in early 2025 found that 48 percent of compounded semaglutide and tirzepatide products differing from the brands were combinations with nutrients or other drugs, and found little justification for adding nutrients (Belcourt 2026).

The oral compounded products are untested. Mochi's compounded semaglutide pill is taken once a week, while the approved Wegovy pill is taken daily, as Mochi's own product cards state. Its compounded orforglipron contains the active ingredient of Foundayo, Lilly's daily pill approved in 2026, which Mochi also sells from $149 (Mochi home page). PubMed searches we ran on October 10, 2026 found no published human study of compounded orforglipron or of a once-weekly compounded oral semaglutide pill.

Peptides and longevity. Sermorelin injections start at $199 a month (500 mcg is listed, other doses at the provider's discretion), NAD+ injections at $135, an NAD+ nasal spray at $83 and an NAD+ cream at $54, alongside two copper-peptide products sold as cosmetics (Mochi medication pages). Sermorelin is legally compoundable and NAD+ is compounded under FDA's interim policy, as our legal tracker records. Among the 58 medication pages in Mochi's sitemap we found no BPC-157, TB-500 or other peptide that no pharmacy may compound. The sermorelin page we read does not mention IGF-1 testing, the one objective check that the drug is working; our sermorelin profile covers the injected doses that were studied, and our NAD+ profile what the injections have been tested for.

Pricing in brief

You pay a membership and, separately, the medication. Medication is priced by the dose prescribed, with shipping included (Mochi FAQ): compounded semaglutide injections from $60 to $99 a month and compounded tirzepatide from $90 to $199, figures Mochi published in August 2026 when it replaced flat prices of $99 and $199 (Mochi per-dose pricing). The membership costs $79 month to month, $207 for three months, $354 for six or $588 for twelve; the insured plan costs $119 for six months or $199 for twelve, with visits billed to insurance (Mochi FAQ). New patients were offered a $39 first month on the weight-loss page, while a banner across the site the same day offered the first month free on the one-month plan (Mochi weight-loss page).

At month-to-month rates, compounded semaglutide costs $139 to $178 a month all-in and compounded tirzepatide $169 to $278. Brand drugs cost the manufacturer's cash price or your copay, plus the membership.

Clinicians, visits and labs

Care begins with a questionnaire and a live 30-minute video visit with a provider you choose from Mochi's directory, which the FAQ says to expect within a week of signing up; you can switch providers later (Mochi weight-loss page; Mochi FAQ). Mochi counts more than 400 board-certified providers and offers registered dietitians, unlimited visits within the membership and round-the-clock support (Mochi home page). The free membership tier described in the terms excludes one-to-one video visits (Mochi terms).

Labs are described as options within the plan and as a recheck later in the program (Mochi FAQ). We found no lab requirement before a GLP-1 or sermorelin prescription, which is common for weight-loss telehealth and a gap for sermorelin.

Where the medication comes from

Mochi does not name the pharmacies that fill its prescriptions on any public page we read. Its weight-loss page tells patients to compare pharmacies and find the best price (Mochi weight-loss page); its pharmacy-partner page recruits pharmacies to a Mochi marketplace in which patients and providers choose from each pharmacy's formulary (Mochi pharmacy page); its terms let prescriptions be filled by and transferred between any of the partner pharmacies (Mochi terms); and its pricing article says the price can depend on which compounding pharmacy fills the order (Mochi per-dose pricing). Whether a given product comes from a 503A pharmacy or a 503B outsourcing facility, and whether a certificate of analysis is available, is not stated.

A marketplace can show the pharmacy at checkout, which we could not see without signing up. Before paying, ask which pharmacy will fill the order, in which state, and whether it is 503A or 503B, and look up its license with your state board of pharmacy. A change of pharmacy can mean a new vial concentration, so check the units on every label with our units converter.

Cancellation, refunds and the fine print

• Cancel any time, but not by email. The terms allow cancellation through the account or by phone; emailed requests are not valid. Cancellation takes effect at the end of the current paid term, so prepaid months are not returned, and the account drops to the free tier (Mochi terms).
• Refunds are discretionary. Partly used periods are not refunded except at Mochi's discretion, never for a month in which you saw a provider, and medication fees are non-refundable once the order reaches a pharmacy. The refund page says all prescription sales are final (Mochi refunds).
• Medication renews automatically. Medication subscriptions are charged monthly at the price on the day the order is processed, which Mochi may change; cancel before the refill request goes to the pharmacy.
• HSA and FSA. The FAQ answers 'Yes' to paying the membership from an HSA or FSA (Mochi FAQ); the terms say the membership fee is not a covered benefit under most plans, including HSA and FSA accounts.
• Disputes go to individual arbitration, with a 30-day window to opt out by email or mail and a one-year limit on bringing claims (section 12).

FDA record and the 2026 legal picture

No warning letter found. On October 10, 2026 FDA's warning-letter database returned two results for 'mochi', neither addressed to Mochi Health: a 2023 letter to a vape company called Mochivap and a 2022 letter to an e-liquid maker that mentioned a flavor named Mochi. Searches for Mochi Health, Mochi Health Corp, Mochi Medical and joinmochi returned nothing else (FDA database). The same database returned the February 2026 letter to Ivim Health, so the 2026 telehealth letters are indexed, and Mochi does not appear to have been among the 55 telehealth companies FDA warned over compounded GLP-1 marketing in 2026.

How the compounded program fits the rules. Since the shortages ended, compounded semaglutide and tirzepatide are lawful only when a licensed 503A pharmacy prepares them for a named patient whose prescriber documents a clinically significant difference from the approved drug; routine copies are not, and FDA has said price is not such a difference, as our tracker and legal explainer set out. A different dose step is not by itself a patient-specific reason, and FDA's 2026 actions treated add-ins such as B12 or niacinamide as insufficient on their own. Mochi presents its compounded drugs as prescribed at the provider's discretion with additives chosen per patient; whether a given prescription meets the test depends on the reason written on it, which no website shows. Ask your prescriber what reason is on yours.

Orforglipron. Foundayo is now a commercially available approved drug, so the same section 503A limit on compounding copies of commercially available drugs applies to compounded orforglipron. Our tracker does not yet assess orforglipron, so we draw no further conclusion.

Ratings

On October 10, 2026 Trustpilot showed a TrustScore of 4.5 out of 5 from 19,304 reviews (Trustpilot). We could not retrieve a Better Business Bureau profile, so we give no BBB figure. Mochi says it has more than 500,000 members, and the testimonials on its own pages come from members Mochi discloses were compensated (Mochi home page). Star averages measure satisfaction with service, not the quality or legality of a medication.

What Mochi's outcome claims rest on

The home page shows a 16 percent average first-year weight loss, self-reported by members and labeled illustrative; the FAQ says about 15 percent (Mochi home page). Mochi's per-dose pricing page places an average of 15 percent from clinical trials next to compounded semaglutide, citing STEP 1, which randomized 1,961 adults to Novo Nordisk's semaglutide 2.4 mg or placebo for 68 weeks and found a mean change of minus 14.9 versus minus 2.4 percent (Wilding 2021). It places 10 to 15 percent at six months next to compounded tirzepatide, citing an insurance-claims analysis by Eli Lilly employees that found an 11.9 percent mean loss at six months among people who stayed on tirzepatide that long (Hankosky 2025). Neither study reports on a compounded product, and self-reported member averages have no comparison group.

Pros

• Publishes a dose-by-dose price table for compounded semaglutide and tirzepatide, with shipping included.
• Live 30-minute video visits with a provider you choose, plus dietitians and unlimited visits.
• Brand GLP-1s, insurance-billed visits, prior-authorization help and Medicare GLP-1 Bridge support under one membership.
• A month-to-month membership option, and cancellation that takes effect at the end of the paid month or term.
• No FDA warning letter found, and no peptides on its menu that no pharmacy may compound.
• Labels compounded products as not FDA-approved and discloses that testimonials were paid.

Cons

• Does not name its pharmacies; the pharmacy, and the price, can vary, and 503A or 503B status is not stated.
• Compounded formulations often include additives that do not by themselves make a compounded GLP-1 lawful.
• Dose steps that differ from the brands, a top tirzepatide step above the label maximum, and oral compounded products with no published human data.
• No refunds for partly used periods, medication final once sent, no cancellation by email.
• Pages disagree on the first-month offer and on HSA and FSA eligibility.
• Marketing places brand-drug study results next to compounded products.

Who it may suit

Mochi fits an adult who wants a live video visit, a choice of clinician and dietitian support, published per-dose prices and the option to pay month to month, and who has discussed with the prescriber why a compounded drug rather than the brand is right for them. It also fits an insured patient who wants visits billed to insurance and help with a brand GLP-1 prior authorization, or a Medicare Part D enrollee exploring the GLP-1 Bridge (Mochi Medicare page). It fits less well if you want to know the pharmacy before you pay, want no membership, want refunds for unused time, or want an oral compounded product with published human data.

Alternatives

Our Mochi Health alternatives guide compares seven telehealth services from our directory of online peptide clinics and our Ivim review on the same criteria, plus the manufacturer cash programs for brand GLP-1s, which need a prescription but no membership. Brand and compounded price benchmarks are in our tirzepatide cost guide and peptide therapy cost guide; the whole process, from evaluation to monitoring, is in our peptide therapy guide.

Bottom line

Mochi Health is a large GLP-1 telehealth platform with unusually open per-dose pricing, live video visits and a cheap membership if you prepay, and FDA's database showed no warning letter against it on October 10, 2026. It is less open about where its medication comes from: no pharmacy is named, the pharmacy can change, and the compounded formulas often carry additives that do not change their legal footing. Before paying, get four things in writing: the medication price at the dose you are likely to reach, the pharmacy and its 503A or 503B status, the clinical reason for a compounded drug rather than the brand, and what happens to prepaid months if you cancel. Run the dose and vial concentration through the peptide calculator when the first vial arrives.

Frequently asked questions

+−Is Mochi Health legit?

It is a real telehealth company, Mochi Health Corp. of San Francisco, whose clinicians belong to affiliated medical practices licensed in the states they serve. It publishes its membership and per-dose medication prices, offers live video visits, and FDA's warning-letter database showed no letter addressed to it on October 10, 2026. It does not name the pharmacies that fill its prescriptions, and a compounded semaglutide or tirzepatide prescription is lawful only with a documented, patient-specific reason, which you should ask your Mochi prescriber to put in writing.

+−What is Mochi Health?

A membership telehealth platform focused on GLP-1 weight care. On October 10, 2026 it listed compounded semaglutide (injection and a once-weekly pill), compounded tirzepatide and orforglipron, the brand GLP-1 drugs, metformin, sermorelin and NAD+, plus hair, skin, mental-health, menopause and men's-health care. Mochi Health Corp. provides administrative and technology services; the medical care comes from affiliated practices.

+−How much does Mochi Health cost?

A membership plus medication. The membership was $79 month to month ($39 for a new patient's first month on some pages), $207 for three months, $354 for six or $588 for twelve; an insured plan cost $119 for six months or $199 for twelve, with visits billed to insurance. Compounded semaglutide cost $60 to $99 a month and compounded tirzepatide $90 to $199, by dose, shipping included. Our Mochi cost breakdown works out the first three months.

+−Does Mochi take insurance?

For visits and brand drugs, often. Its insured plan bills provider visits to insurance and shows the copay first, its team handles prior authorizations for brand GLP-1s, and a Medicare page helps Part D enrollees apply for the GLP-1 Bridge. Compounded medications are cash. The FAQ says HSA and FSA cards can pay the membership; the terms say the membership fee is not a covered benefit under most plans, including HSA and FSA.

+−What pharmacy does Mochi Health use?

Mochi does not name its pharmacies on its public pages. It runs a pharmacy marketplace in which patients compare pharmacies and prices, its terms allow prescriptions to be filled by and transferred between any of its partner pharmacies, and its pricing article says the price can depend on which compounding pharmacy fills the order. Ask which pharmacy, in which state, and whether it is a 503A pharmacy or a 503B outsourcing facility before you pay.

+−Has Mochi Health received an FDA warning letter?

None was found. On October 10, 2026 FDA's warning-letter database returned two results for 'mochi', a 2023 letter to a vape company called Mochivap and a 2022 letter to an e-liquid maker about a flavor named Mochi, and searches for Mochi Health, Mochi Health Corp and Mochi Medical found no other letter. The same database lists the 2026 letters to telehealth companies over compounded GLP-1 marketing, so Mochi does not appear to have been among them.

+−Is the FDA banning compounded semaglutide?

No single ban was issued. The semaglutide shortage ended in February 2025, after which a compounded version is lawful only when a 503A pharmacy prepares it for a patient whose prescriber documents a clinical need the approved drug cannot meet. FDA sent 55 warning letters over compounded GLP-1 marketing in 2026 and proposed in May 2026 to keep semaglutide off the list outsourcing facilities may use. Mochi's compounded semaglutide falls under those rules like anyone else's.

+−Can telehealth prescribe peptides?

Yes, for peptides a licensed pharmacy may legally compound or a manufacturer makes, by a clinician licensed in your state. Mochi prescribes sermorelin injections and the GLP-1 drugs; we found no BPC-157, TB-500 or other peptide that no pharmacy may compound among its medication pages on October 10, 2026.

+−How do I cancel Mochi Health?

Through 'cancel subscription' in your account or by phone; Mochi's terms say email cancellation requests are not valid. Cancellation takes effect at the end of the current paid term and the account reverts to a free membership. Mochi does not refund partly used subscription periods except at its discretion, and medication is non-refundable once the order goes to a pharmacy.

+−What are Mochi Health reviews like?

On October 10, 2026 Trustpilot showed a TrustScore of 4.5 out of 5 from 19,304 reviews. We could not retrieve a Better Business Bureau profile. Testimonials on Mochi's own site come from members Mochi says were compensated. Star averages measure satisfaction with service, not the quality or legality of a medication.

Sources

1. SourceMochi Health. Home page (product cards with starting prices and dose steps, membership pricing panel, '500,000+ members', '400+ board certified', self-reported 16% first-year weight loss, compensated-testimonial notice, corporate footer). Read October 10, 2026. (2026)
2. SourceMochi Health. Frequently asked questions (membership prices, Covered With Mochi plan, per-dose medication prices, shipping, HSA and FSA, first visit timing, eligibility, pediatrics, labs). Read October 10, 2026. (2026)
3. SourceMochi Health. Weight loss page ($39 first month then $79, 30-minute video visit, compare pharmacies, product list). Read October 10, 2026. (2026)
4. SourceMochi Health. Medication pages: compounded tirzepatide, compounded semaglutide, compounded semaglutide pill, compounded orforglipron, Zepbound, Wegovy, Foundayo, sermorelin, NAD+, and the longevity page. Read October 10, 2026. (2026)
5. SourceMochi Health. Medicare GLP-1 Bridge page (eligibility help, prior authorization, retail pharmacy or LillyDirect fulfilment). Read October 10, 2026. (2026)
6. SourceMochi Health. New per-dose pricing on Mochi Health: what changed and why (dose-by-dose price tables as of August 2026). Published August 15, 2026, updated September 18, 2026; with the per-dosage pricing page. Read October 10, 2026. (2026)
7. SourceMochi Health. GLP-1 additives: tirzepatide with L-carnitine, B12 and NAD+ (blog). Published November 21, 2025, updated September 18, 2026. Read October 10, 2026. (2026)
8. SourceMochi Health. Pharmacy partners page (pharmacies join the Mochi Marketplace; patients and providers choose from their formularies). Read October 10, 2026. (2026)
9. SourceMochi Health. Terms of use, updated September 22, 2026 (sections 3, 4, 7 and 12: pharmacies, subscription fees, cancellation and refunds, use of the services, arbitration). Read October 10, 2026. (2026)
10. SourceMochi Health. Refunds and returns (all prescription sales final). Read October 10, 2026. (2026)
11. RegulatoryFDA. Warning letters database, searched October 10, 2026 for 'mochi', 'Mochi Health', 'Mochi Health Corp', 'Mochi Medical' and 'joinmochi': no letter addressed to Mochi Health or its affiliated practices (the two results for 'mochi' were a 2023 letter to Mochivap and a 2022 letter to Cyberliquids, LLC). (2026)
12. SourceTrustpilot. Mochi Health reviews (TrustScore 4.5 out of 5, 19,304 reviews). Read October 10, 2026. (2026)
13. StudyWilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. (2021)
14. StudyHankosky ER, Chinthammit C, Meeks A, et al. Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: results from the Optum Market Clarity database. Diabetes Obes Metab 2025;27:2810-21. (2025)
15. StudyBelcourt J, Sapowadia A, White CM. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother 2026;60:902-6. (2026)